AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Mar 19, 2023

Warts and all

New approaches, existing therapies tackle those stubborn skin disorders.


Peter Friedman, MD, PhD, FAAD
Peter Friedman, MD, PhD, FAAD

Every dermatologist at some point in their career will run into that most pernicious of protrusions — the stubborn wart that just won’t go away.

Peter Friedman, MD, PhD, FAAD, a dermatologist at the Skin Center Dermatology Group in New City, New York, and instructor in clinical dermatology at Columbia University – New York Presbyterian Hospital, said hard-to-manage warts are a daily occurrence in his practice, in part because he sees many children. Dr. Friedman said there are several possible explanations for poor outcomes in managing warts.

Speaking at Friday’s session, “U028 – The Evolving Toolbox for Treating Difficult Warts,” Dr. Friedman took on the tough issues. 

Where did that wart come from?

“Sometimes there is an explanation, like the lesions are very big or they are in areas where traditional treatments can’t be used to the fullest extent,” he said. “The side effects or the logistics associated with traditional treatments can also reduce [patient] compliance, and occasionally underlying medical issues, such as immunosuppression, reduce the efficacy of treatments. However, sometimes there is no obvious reason — the wart just doesn’t get better.” 

Two-fold approach

Dr. Friedman takes a twofold approach when it comes to tackling the toughest warts. 

“First, I do not do the ‘first-line treatment, second-line treatment after failure’ approach,” he said. “I try to look at every wart patient with all the treatment options in mind and recommend a plan that uniquely suits their individual scenario.”

The second prong of his attack involves a combination of treatments.

“I use the traditional methods — I do freeze many warts and I do recommend using over-the-counter salicylic acid products, but almost never as monotherapy and only when that seems more appropriate for the given patient than anything else I can offer,” he said. “It has been my experience, which is also supported by a number of studies, that certain combination treatments can work better than monotherapies.”

New treatments now and on the horizon

Dr. Friedman discussed several evolving methods that are showing promising results for wart treatment, along with one new one that he said is matching some traditional treatments in terms of efficacy.

“One of the truly novel methods is cold atmospheric plasma, which was developed by a research team I am part of,” he said. “This is a very well-tolerated treatment with efficacy on par with the more traditional treatments. The limitation is that it does require a device to administer the treatment, and it is not yet on the market.”

Patient considerations

Ultimately, Dr. Friedman said there are multiple factors to consider when treating stubborn warts, not the least of which is the cost to the patient.

“Cost is a very important question and can be a significant barrier,” he said. “If we prescribe a medication, the patient may or may not have a co-pay. If they come to the office for treatment, they may or may not have a co-pay or deductible. One part of their benefit package may be more favorable than the other, depending on their insurance. They may live far from the office or work multiple jobs, so it is a big issue to come to see me every three or four weeks for a treatment.”

Aside from the cost of the office visit, Dr. Friedman said the cost of just getting to the office and the monetary value of the time patients have to spend on office visits can add up quickly. 

“These variables, and not just the purely medical considerations, all factor into the decision process when choosing the best treatment for a patient,” he said. “So there really is no one treatment I would recommend above all for all patients.

“We must constantly remind ourselves that our most commonly used first-line wart treatments are far from perfect, as large reviews and analyses have shown time and time again,” Dr. Friedman said.  

Visit AAD DermWorld Meeting News Central for more articles.

Interesting Stories
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
More in AAD 2023 Annual Meeting
Safi Bahcall
AAD 2023 Annual Meeting
Nurture the unexpected
Mar 20, 2023
Richard L. Gallo, MD, PhD, FAAD
AAD 2023 Annual Meeting
New approach uses microbiome to treat skin disease
Mar 20, 2023
Camp Discovery 92
AAD 2023 Annual Meeting
Refer a patient to Camp Discovery!
Mar 20, 2023
Amy J. McMichael, MD, FAAD
AAD 2023 Annual Meeting
A question of belonging
Mar 20, 2023
David J. Margolis, MD, PhD, FAAD
AAD 2023 Annual Meeting
Dermatologists top the list in antibiotic prescriptions
Mar 20, 2023
22 698 Ia23 Web Card 3x2
AAD 2023 Annual Meeting
Mark your calendar for Innovation Academy 2023
Join the learning
Mar 20, 2023
Getty Images 479036574
AAD 2023 Annual Meeting
Save the date for the 2024 Annual Meeting
Mark you calendar for AM2024
Mar 20, 2023
2022 03 21 12 20 34 6238b40dd1e28
AAD 2023 Annual Meeting
Access your Certificate of Attendance
Download online
Mar 20, 2023
2022 03 21 12 26 25 6238b55bf2d38
AAD 2023 Annual Meeting
Claim CME
Claim CME
Mar 20, 2023
Aad March20
AAD 2023 Annual Meeting
Session highlights for Monday
Mar 20, 2023
Jane Margaret Grant-Kels, MD, FAAD
AAD 2023 Annual Meeting
Ethical dilemmas hiding in plain sight
Mar 20, 2023
John T. Schiller, PhD
AAD 2023 Annual Meeting
Taking on cervical cancer, one shot at a time
Mar 20, 2023
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.